{'fraction_non_alphanumeric': 0.026515151515151516, 'fraction_numerical': 0.015151515151515152, 'mean_word_length': 5.445121951219512, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ticlopidine impairs phenytoin clearance

Ticlopidine is an antiplatelet agent used in the prophylaxis of peripheral and cerebrovascular diseases, [1-3] ischemic heart disease, [1,3] and vascular complications of diabetes mellitus. [4] In healthy volunteers ticlopidine reduces the clearance of theophylline [5] and antipyrine, [6] probably by inhibiting the activity of cytochrome P450 enzymes. On the basis of these observations, the package insert in some countries contains a warning advising caution when ticlopidine is introduced in patients receiving therapy with highly metabolized drugs.

We report a case of metabolic phenytoin-ticlopidine interaction in which phenytoin plasma concentrations increased and CNS toxicity appeared when ticlopidine was added to the therapeutic regimen.

A 65-year-old man had a history of complex partial seizures, sometimes with secondary generalization, which started at the age of 52 years. A brain CT scan obtained at this time was normal. He had been treated with different antiepileptic regimens for about 10 …